Literature DB >> 17945349

Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.

Sara Tengvall1, Ali M Harandi.   

Abstract

Toll-like receptors (TLRs) play an important role as pattern-recognition receptors to sense and respond to pathogens. Our laboratory and others have shown recently that activation of TLR/MyD88 signaling through vaginal administration of CpG oligodeoxynucleotides, either singly or in combination with recombinant glycoprotein from herpes simplex virus type 2 (HSV-2), confers immunity against genital herpes infection. In this study, we have investigated the importance of the myeloid differentiation factor 88 (MyD88), a critical adaptor protein shared by all TLRs, in innate and acquired immunity against genital HSV-2 infection in mice. We demonstrate that MyD88 is essential for innate immune resistance against HSV-2. Thus, MyD88 deficient (MyD88(-/-)) mice show more vaginal HSV-2 titers, more rapid disease progression and earlier death compared to C57Bl/6 mice following a vaginal challenge with high (9 x 10(4) PFU) or low (9 x 10(3) PFU) virus dose. In contrast, use of MyD88 appears dispensable for induction of HSV-specific serum IgG antibody as well as local and systemic cell-mediated immune responses elicited by vaginal immunization with live attenuated thymidine kinase-deficient HSV-2 (HSV-2 TK(-)). Importantly, and similar to immunized C57Bl/6 mice, immunized MyD88(-/-) mice were completely protected against subsequent vaginal challenge with a lethal dose of virulent strain of HSV-2. These results provide evidence that the adaptor protein MyD88 is important for innate early control of genital HSV-2 infection, and that use of MyD88 is not required for induction of acquired immunity following vaginal immunization with HSV-2 TK(-).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945349     DOI: 10.1016/j.jri.2007.09.001

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  6 in total

1.  Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.

Authors:  Xiuli Zhang; Xavier Dervillez; Aziz Alami Chentoufi; Tina Badakhshan; Ilham Bettahi; Lbachir Benmohamed
Journal:  J Immunol       Date:  2012-09-26       Impact factor: 5.422

2.  A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Authors:  X Zhang; A A Chentoufi; G Dasgupta; A B Nesburn; M Wu; X Zhu; D Carpenter; S L Wechsler; S You; L BenMohamed
Journal:  Mucosal Immunol       Date:  2008-12-24       Impact factor: 7.313

3.  The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus.

Authors:  Yuan Zhao; Carl De Trez; Rachel Flynn; Carl F Ware; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

4.  Finding quasi-modules of human and viral miRNAs: a case study of human cytomegalovirus (HCMV).

Authors:  Isana Veksler-Lublinsky; Yonat Shemer-Avni; Eti Meiri; Zvi Bentwich; Klara Kedem; Michal Ziv-Ukelson
Journal:  BMC Bioinformatics       Date:  2012-12-03       Impact factor: 3.169

Review 5.  Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans.

Authors:  Horst von Bernuth; Capucine Picard; Anne Puel; Jean-Laurent Casanova
Journal:  Eur J Immunol       Date:  2012-12       Impact factor: 5.532

Review 6.  Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virus.

Authors:  Erdenebileg Uyangaa; Ajit Mahadev Patil; Seong Kug Eo
Journal:  Immune Netw       Date:  2014-08-22       Impact factor: 6.303

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.